ProKidney Corp.

NasdaqCM PROK

ProKidney Corp. Price to Book Ratio (P/B) on January 14, 2025: -1.75

ProKidney Corp. Price to Book Ratio (P/B) is -1.75 on January 14, 2025, a -243.37% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

ProKidney Corp. 52-week high Price to Book Ratio (P/B) is -0.43 on February 13, 2024, which is 75.39% above the current Price to Book Ratio (P/B).
ProKidney Corp. 52-week low Price to Book Ratio (P/B) is -2.20 on December 16, 2024, which is -26.03% below the current Price to Book Ratio (P/B).
ProKidney Corp. average Price to Book Ratio (P/B) for the last 52 weeks is -1.08.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: PROK

ProKidney Corp.

CEO	Dr. Bruce Culleton M.D.
IPO Date	June 30, 2021
Location	United States
Headquarters	2000 Frontis Plaza Blvd.
Employees	163
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key trends

Past 5 years